Spots Global Cancer Trial Database for advanced kidney cancer
Every month we try and update this database with for advanced kidney cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | NCT03540199 | Advanced Kidney... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | NCT03308396 | Advanced Kidney... Kidney Cancer Clear Cell Rena... | Guadecitabine Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer | NCT01114230 | Renal Cell Carc... Pharmacokinetic... | AGS-16M8F | 18 Years - | Astellas Pharma Inc | |
| A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer | NCT01114230 | Renal Cell Carc... Pharmacokinetic... | AGS-16M8F | 18 Years - | Astellas Pharma Inc | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | NCT04337970 | Kidney Cancer Renal Cell Carc... Unresectable Re... Metastatic Rena... | Talazoparib Axitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | NCT03540199 | Advanced Kidney... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | NCT03308396 | Advanced Kidney... Kidney Cancer Clear Cell Rena... | Guadecitabine Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Tislelizumab Plus Lenvatinib in Stage III-IV RCC | NCT05485883 | Advanced Kidney... | Tislelizumab Le... | 18 Years - | Tianjin Medical University Second Hospital | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | NCT04337970 | Kidney Cancer Renal Cell Carc... Unresectable Re... Metastatic Rena... | Talazoparib Axitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal | NCT00831480 | Kidney Cancer | everolimus | 18 Years - | Baylor College of Medicine | |
| Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma | NCT00903175 | Renal Cell Carc... | everolimus sunitinib | 18 Years - | Novartis | |
| Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal | NCT00831480 | Kidney Cancer | everolimus | 18 Years - | Baylor College of Medicine | |
| Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma | NCT00903175 | Renal Cell Carc... | everolimus sunitinib | 18 Years - | Novartis | |
| Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal | NCT00831480 | Kidney Cancer | everolimus | 18 Years - | Baylor College of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
